| abstract |
The present invention relates to a substituted pyrazolopyrimidine compound that inhibits casein kinase 1ε (CK1ε) activity, a stereoisomer or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt or solvate thereof, and casein kinase 1ε (CK1ε) It provides application in the manufacture of a medicament to treat a disease, disorder or condition that would benefit from inhibition of activity. The compound has inhibitory activity against CK1ε kinase, OCI-LY10 cells and Karpas299 cells, and exhibits excellent antitumor activity in the OCI-LY10 subcutaneous xenogeneic model, and exhibits excellent synergistic antitumor activity when used together with a BTK inhibitor. The compounds have relatively good pharmacokinetic properties and can be used alone or in combination with other drugs to treat diseases, disorders or conditions that benefit from inhibition of casein kinase 1ε activity, including cancer, autoimmune diseases, and the like. |